Puntoriero G, Meola A, Lahm A, Zucchelli S, Ercole B B, Tafi R, Pezzanera M, Mondelli M U, Cortese R, Tramontano A, Galfre' G, Nicosia A
Istituto di Ricerche di Biologia Molecolare P.Angeletti, Via Pontina Km 30.600, 00040 Pomezia (Roma).
EMBO J. 1998 Jul 1;17(13):3521-33. doi: 10.1093/emboj/17.13.3521.
The hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) is the most variable antigenic fragment in the whole viral genome and is mainly responsible for the large inter-and intra-individual heterogeneity of the infecting virus. It contains a principal neutralization epitope and has been proposed as the major player in the mechanism of escape from host immune response. Since anti-HVR1 antibodies are the only species shown to possess protective activity up to date, developing an effective prevention therapy is a very difficult task. We have approached the problem of HVR1 variability by deriving a consensus profile from >200 HVR1 sequences from different viral isolates and used it as a template to generate a vast repertoire of synthetic HVR1 surrogates displayed on M13 bacteriophage. This library was affinity selected using many different sera from infected patients. Phages were identified which react very frequently with patients' sera and bind serum antibodies that cross-react with a large panel of HVR1 peptides derived from natural HCV variants. When injected into experimental animals, the 'mimotopes' with the highest cross-reactivity induced antibodies which recognized the same panel of natural HVR1 variants. In these mimotopes we identified a sequence pattern responsible for the observed cross-reactivity. These data may hold the key for future development of a prophylactic vaccine against HCV.
丙型肝炎病毒(HCV)假定包膜蛋白E2的高变区1(HVR1)是整个病毒基因组中最具变异性的抗原片段,主要导致感染病毒在个体间和个体内存在巨大的异质性。它包含一个主要的中和表位,被认为是病毒逃避宿主免疫反应机制中的主要因素。由于抗HVR1抗体是迄今为止唯一显示具有保护活性的抗体类型,因此开发有效的预防疗法是一项非常艰巨的任务。我们通过从200多个来自不同病毒分离株的HVR1序列推导共有图谱来解决HVR1变异性问题,并将其用作模板来生成展示在M13噬菌体上的大量合成HVR1替代物库。使用来自感染患者的多种不同血清对该文库进行亲和筛选。鉴定出与患者血清反应非常频繁且结合与大量源自天然HCV变体的HVR1肽交叉反应的血清抗体的噬菌体。当注射到实验动物体内时,具有最高交叉反应性的“模拟表位”诱导出能识别相同天然HVR1变体组的抗体。在这些模拟表位中,我们鉴定出一种导致观察到的交叉反应性的序列模式。这些数据可能是未来开发抗HCV预防性疫苗的关键。